Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Czechia
Czechia- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
23 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Czechia
Czechia- Participants:18–64 years
Recruiting
Dementia Alzheimer's type
RecruitingInvestigational
A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease
Investigational
- Disease:Dementia Alzheimer's type
- Substances:Trospium ChlorideXanomeline Tartrate
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Trospium Chloride
Recruiting
Dementia Alzheimer's type
RecruitingInvestigationalNo placebo
Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation
InvestigationalNo placebo
- Disease:Dementia Alzheimer's type
- Substances:Trospium ChlorideXanomeline Tartrate
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Trospium Chloride
Recruiting
Torticollis
RecruitingInvestigational
Study on IPN10200 for Treating Cervical Dystonia in Adults
Investigational
- Disease:Torticollis
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Recruiting
InvestigationalNo placebo
Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
InvestigationalNo placebo
- Disease:Dementia of the Alzheimer's type with delusions
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Recruiting
Dementia with Lewy bodies
RecruitingInvestigationalNo placebo
A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis
InvestigationalNo placebo
- Disease:Dementia with Lewy bodies
- Substances:Acp-204 Tartrate
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Acp-204 Tartrate
Recruiting
Dementia with Lewy bodies
RecruitingInvestigational
A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis
Investigational
- Disease:Dementia with Lewy bodies
- Substances:Acp-204 Tartrate
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Acp-204 Tartrate
- Disease:Dementia of the Alzheimer's type with delusions
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Recruiting
Dementia Alzheimer's type
RecruitingInvestigational
Study on ITI-1284 for Treating Agitation in Alzheimer's Patients
Investigational
- Disease:Dementia Alzheimer's type
- Substances:Iti-1284
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Iti-1284
Recruiting
Dementia Alzheimer's type
RecruitingInvestigationalNo placebo
Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis
InvestigationalNo placebo
- Disease:Dementia Alzheimer's type
- Substances:Acp-204 Tartrate
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Acp-204 Tartrate
Not yet recruiting
Parkinson's disease
Not yet recruitingRegistered drug
A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease
Registered drug
- Disease:Parkinson's disease
- Substances:Ioflupane (123I)
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Ioflupane (123I)